BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

Afferon Corporation

Afferon is a privately held pharmaceutical company building a specialty pharmaceutical business focused on urology. Afferon has completed the necessary pre-clinical work on its lead candidate, resiniferatoxin, and has shown proof of principle in Phase I/IIa human clinical trials in urinary urge incontinence and diabetic neuropathy pain. Several large Phase II trials are underway in the U.S. and Europe.


Contact Details:
200 Eagle Road, Suite 200
Wayne
PA
19087
United States of America
Tel:610-971-2555
Fax:610-971-2559
Email:
WWW:

www.afferon.com/




Loading...

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 510 times since April 2007, the link to the organisation's website has been followed 106 times

Recent Search Terms used to find this page: Afferon | Afferon | Afferon Corporation | Afferon Corp | afferon | t | afferon corp | Afferon Corp | afferon corporation | afferon | .

Search for more companies in Wayne

Search for more companies in PA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Afferon Corporation
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.